Company Overview and News

6
Fear and loathing in troubled Thoothukudi

2018-05-29 livemint
“Four hundred beds (worth Rs50 lakh) in this hospital were sponsored by Sterlite Industries,” reads a plaque, written in Tamil, on the wall facing the entrance to the fifth floor of the Government Medical College and Hospital in Thoothukudi.
HNDZY MRZUY VEDL 532500 VED MARUTI LNSTY 500570 TATAMOTORS 500188 HINDZINC SBAZ TTM

14
Anil Agarwal wants to build Vedanta into giant producer of commodities to rival majors

2018-05-27 livemint
London: Billionaire industrialist Anil Agarwal plans to leave behind a legacy: an Indian resources group to rival the world’s biggest.
AULGF VED AAUKF AU HNDZY AAL AGG NGLOY VEDL 500188 HINDZINC

1
Hind Zinc slumps after muted Q4

2018-05-02 premium.thehindubusinessline
The stock of Hindustan Zinc fell by 5.8 per cent on Wednesday, owing to a drop in the March quarter net profit by 18 per cent y-o-y. The weak production guidance given by the company for fiscal 2018-19 has further dampened sentiments. However, a ramp-up in production in the company’s underground mines, higher consistency in grade levels and expected lower cost of production over the next two to three years, remain positives for the stock.
HNDZY 500188 HINDZINC

43
Sensex ends flat ahead of Fed rate decision, but Mid-Smallcap indices slip sharply

2018-05-02 moneycontrol
Benchmark indices ended rangebound session on a flat note Wednesday but the broader markets underperformed, with the Nifty Midcap index falling 1.5 percent and BSE Smallcap declining over a percent amid earnings.
INDIANB 500325 HCTHY JUSTDIAL 532483 532281 EICHERMOT RLNIY AXB JETAIRWAYS YYBKY CNRYY 500182 AXBA TATASTEEL FORTIS TATLY HCLTECH 500180 KOTAKBANK 534809 PCJEWELLER CANBK 500188 HINDZINC GODREJIND RELIANCE 532617 532814 HNDZY 532215 505200 532541 500470 535648 AXISBANK RIGD HDFCBANK HEROMOTOCO YESBANK NIITTECH INDIGO ECQRY KMBKY IBN 532648 532843 539448 AXBKY ICICIBANK TTST HDB 532174 HRTQY 500247 500164 JSTQY

1
Hindustan Zinc Limited - Financial Result Updates

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HNDZY 500188 HINDZINC

1
Hindustan Zinc hits 3-week low

2018-05-02 thehindubusinessline
The company, a unit of Vedanta Ltd, has posted a 18 per cent drop in fourth-quarter net profit.
HNDZY VEDL 500188 HINDZINC

5
Potash Ridge Appoints E. Richard Klue to Board of Directors

2018-05-01 globenewswire
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Potash Ridge Corporation (the “Company”) (TSX:PRK) is pleased to announce the addition of E. Richard Klue, B.Com, NHD Ext.Met. to the Board of Directors of Potash Ridge Corporation.
PRK POTRF AAUKF CCK HNDZY AAL CCB BRUZF NGLOY CDCLD 500188 HINDZINC

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...